34 results
425
EQRX
EQRx, Inc.
23 Oct 23
Business combination disclosure
6:13am
whether to test the 500 mg daily dose level as we are still evaluating 400 mg daily. Recall that doses below 80 mg daily were not expected to be associated … .
[Slide 15]
Recall that the RMC-6236-001 study is a first-in-human Phase 1 dose escalation study.
Necessarily, the first cohorts of patients were
424B4
b5r5v1c 4yeq
5 Feb 21
Prospectus supplement with pricing info
12:00am
DRS
8kpqry
21 Jan 21
Draft registration statement
12:00am